Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.

A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response ...

Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents. This novel ...

Immune checkpoint inhibitor (ICI) therapy before surgery for hepatocellular carcinoma (HCC) may produce major pathological response in about one-third of the surgical patients. The clinical and ...

People with compromised liver function may be able to reduce their risk of liver cancer or slow its progression with a simple dietary change: eating less protein. A Rutgers-led study in Science ...

Chinese researchers have revealed a mechanism that triggers metastasis of hepatocellular carcinoma (HCC)—the most common type of primary liver cancer—through the production of acetate by ...

Margot got the news in her early 20s: "You have liver cancer," her doctors told her. Specifically, Margot had a form of liver cancer known as fibrolamellar carcinoma, a diagnosis with deadly prospects ...

The global incidence of liver cancer is projected to double by 2050. Sixty percent of liver cancers are preventable by controlling risk factors including hepatitis B and C, alcohol consumption, and ...